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Abstract. In 2006, artemether–lumefantrine (AL) became the first-line treatment of uncomplicated malaria in Senegal,
Mali, and the Gambia. To monitor its efficacy, between August 2011 and November 2014, children with uncomplicated
Plasmodium falciparum malaria were treated with AL and followed up for 42 days. A total of 463 subjects were
enrolled in three sites (246 in Senegal, 97 in Mali, and 120 in Gambia). No early treatment failure was observed and
malaria infection cleared in all patients by day 3. Polymerase chain reaction (PCR)-adjusted adequate clinical and para-
sitological response (ACPR) was 100% in Mali, and the Gambia, and 98.8% in Senegal. However, without PCR adjust-
ment, ACPR was 89.4% overall; 91.5% in Mali, 98.8% in Senegal, and 64.3% in the Gambia (the lower value in the
Gambia attributed to poor compliance of the full antimalarial course). However, pfmdr1 mutations were prevalent in
Senegal and a decrease in parasite sensitivity to artesunate and lumefantrine (as measured by ex vivo drug assay) was
observed at all sites. Recrudescent parasites did not show Kelch 13 (K13) mutations and AL remains highly efficacious
in these west African sites.
INTRODUCTION
Plasmodium falciparum malaria is a major public health
problem, particularly in sub-Saharan Africa. Its control
is threatened by the possible emergence of resistance to
commonly used treatments. Resistance to antimalarials by
P. falciparum has been an ongoing global public health concern
since chloroquine resistance emerged in the 1960s.1 Several
factors such as suboptimal treatment dosage or counterfeit/
substandard medications increase the selective pressure on
the local parasite populations and thus favor the spread of
drug-resistant parasites. The approach of treating malaria
patients with a combination of drugs is thought to decrease
the risk of selecting resistant parasites.2 The artemisinin com-
ponent has a short half-life (< 8 hours) and rapidly reduce
parasite biomass, whereas the partner drug can clear any
remaining parasites. For this reason, malaria-endemic coun-
tries, including those in sub-Saharan Africa, have adopted
artemisinin-based combination therapies (ACT) as first-line
treatments for uncomplicated malaria.1,3–5 One of these is
artemether–lumefantrine (AL) that has been proven to be
highly efficacious and well tolerated.6–8 Senegal, Mali, and the
Gambia adopted it as first-line malaria treatment in 2006.9
Considering the emergence of artemisinin resistance along
the Thai–Cambodian border,10 treatment efficacy should be
monitored at regular intervals.11 This involves directly mea-
suring parasite drug responses, or indirectly measuring the
prevalence of specific mutations in several parasite genetic
loci associated to lower treatment efficacy.12 Monitoring their
prevalence over time can reveal trends that inform on the
possible therapeutic life of a given treatment.11,13
MATERIALS AND METHODS
This study was carried out between September 2011 and
November 2014 in four sites, two in Senegal (Section de
Lutte AntiParasitaire (SLAP) clinic in Thiès and in Dakar)
and one in each of the other two countries, Dioro in Mali
and Gambissara in The Gambia. The two sites in Senegal
are urban, with low and seasonal (September–November)
P. falciparum malaria transmission. The entomological inocu-
lation rate (EIR) is estimated at < 5.14,15 Dioro is a rural
community at the edge of the Sahel with hyper-endemic, year-
round malaria caused by both the seasonal rainfall (June–July
to October–November) and the irrigation scheme from the
Niger River for the rice fields.16 Gambissara is a large village
in the upper river region (URR) of the Gambia where malaria
transmission is moderate and seasonal (July–December).17,18
Suspected malaria patients were explained the study
objectives and procedures before being asked to sign an
informed consent form. For patients < 18 years old, parents/
guardian were asked to sign the informed consent. Inclusion
criteria were as follows: P. falciparum mono-infection with a
density between 2,000 and 200,000/μL, age between 2 and
15 years in Gambissara and Dioro, and 2–20 years in Thiès
and Dakar. Exclusion criteria included the following: severe
malaria, other acute or chronic potentially confounding dis-
eases, concomitant infection, history of human immunodefi-
ciency virus, and an inability to take oral medicine.
After consenting, a rapid diagnostic test (RDT) (Pf HRP2)
was performed and a thick and thin blood film was collected
for microscopy; hemoglobin was measured by Hemocue® Hb
201+ at days 0 and 28 and glycemia was also determined. A few
drops of blood were collected onWhatman Flinders Technology
Associates (FTA) filter paper cards or ethylenediaminetetra-
acetic acid (EDTA) tubes for later P. falciparum genotyping.19
AL (20 mg of artemether and 120 mg lumefantrine) was
administered twice a day for 3 days according to patient
*Address correspondence to Daouda Ndiaye, Avenue Cheikh Anta Diop
University, POBox 5005,Dakar-Fann. E-mail: dndiaye@hsph.harvard.edu
†These authors contributed equally to this work.
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weight: 5–14 kg, one tablet per dose; 15–24 kg, two tablets per
dose; 25–34 kg, three tablets per dose. Morning doses were
given under direct observation in the study clinic and the rest
was given to the patient to be taken at home. A full dose was
readministered if the patient vomited within 30 minutes; if
patients vomited a second time within 30 minutes, they were
referred for parenteral treatment and withdrawn from the study.
Patients were asked to return for follow-up visits, physical
examinations, and finger prick (for thick and thin blood smear,
and filter paper collection) on days 1, 2, 3, 7, 14, 21, 28, 35,
and 42, as well as any day they felt unwell. Treatment failure
was treated with quinine.
Blood slides were stained with 10% Giemsa and read inde-
pendently by two technicians. Parasite density was estimated
by counting the number of asexual parasites against 200–
500 white blood cells (WBCs) and assuming a WBC count of
8,000/μL.20
DNA extraction for subsequent molecular analysis was
only carried out in Senegal and the Gambia. In Senegal,
DNA was extracted from blood preserved on Whatman FTA
filter paper cards or whole blood EDTA samples using either
a QIAmp DNA or Blood Mini Kit (Qiagen, Valencia, CA),
whereas in the Gambia, whole blood was stored in EDTA
tubes for this analysis. Infections were genotyped according to
published protocols.21,22 As a tool to track parasite diversity,
we used a previously developed “molecular barcode,” com-
posed of assays for 24 single nucleotide polymorphisms (SNPs)
across the P. falciparum genome. The high resolution melting
(HRM) genotyping method detects the presence of sequence
variation in a fragment of amplified DNA using a dsDNA bind-
ing dye and Hi-Res Melting.22,23 Drug resistance–associated
mutations were detected based on changes in DNA sequence,
and are referred to in the text, by their corresponding amino
acid changes.21 Differentiation between recrudescence and
reinfection was assessed by comparing the 24-SNP molecular
barcode between day 0 and day of treatment failure.
We performed Sanger sequencing of the K13 propeller
gene using protocols established in Centers for Disease Con-
trol and Prevention (CDC) Atlanta Malaria Genomic labora-
tory.24 Samples with treatment failure confirmation from
Senegal were analyzed for mutations in the K13 propeller
domain using the Geneious Pro R8 software (Biomatters Inc.,
Newark, NJ). An automated SNP calling workflow developed
in CDC Atlanta using Geneious Pro R8 was used for this anal-
ysis. SNPs were only called if both the forward and reverse
strands had the mutation.
The primary endpoint was treatment efficacy at day 42,
both PCR adjusted and unadjusted, assessed by clinical and
parasitological outcomes using the World Health Organiza-
tion (WHO) definitions for adequate clinical and parasito-
logical response (ACPR), early treatment failure (ETF), late
treatment failure (LTF), late parasitological failure (LPF).25
Secondary endpoints were parasite clearance time by day 3,
time to reinfection, and hemoglobin levels on days 0 and 28.
Resistance markers for AL (pfmdr1 and pfcrt) were mea-
sured in the Gambia and Senegal.
Study forms were double entered. Statistical analysis was
performed using STATA 12 version software (Stata Corp.,
College Station, TX). The per-protocol (PP) analysis excluded
children withdrawn from the study for any reason. Kaplan–
Meier curves were estimated for both the 28- and 42-day
follow-up; the log-rank test was used for comparing the
curves. A two-sided P value < 0.05 was considered as statisti-
cally significant.
The study was reviewed and approved by the respec-
tive institutional review boards (IRBs), and was carried
out according the current WHO Guidelines for Good Clin-
ical Practices.
RESULTS
Out of 1,771 screened patients (704 in Mali, 471 in Senegal,
and 596 in the Gambia) (Table 1), 463 were included in the
study (97 in Mali, 246 in Senegal, and 120 in the Gambia).
Mean Hb at day 0 was 10.9 g/dL and similar between coun-
tries (Table 1).
Among those enrolled, 404 (87.2%) were included in the
day 42 analysis; 84 for Mali (86.5%), 237 for Senegal (96.3%),
and 83 (69.2%) for the Gambia (Table 1). There was no per-
sistent vomiting of medications or persisting symptoms after
day 3 in any of the sites, with no other serious adverse
events detected.
FIGURE 1. Single nucleotide polymorphism (SNP) barcode of parasite isolates from day 0 and day of treatment failure. (A) Barcodes of the
three isolates from Senegal, in which the 24 SNPs were identical at day 0 and day of failure, indicating recrudescence. (B) Example of barcodes
of two isolates from Mali and The Gambia, in which the pattern was different between day 0 and day of failure, indicating reinfection with a dif-
ferent strain of parasite.
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The only other reason for patient withdrawal from the
analysis was lost to follow-up, which concerned 31 (6.7%)
patients (Table 1). Mean hemoglobin level at day 28 improved
from 10.9 ± 1.7 at day 0 to 11.7 ± 1.3, with the same trend
seen in all three countries. Specific values per country were
10.00 ± 1.70 g/dL at day 28 versus 10.80 ± 1.71 g/dL at day
0 in Senegal (P = 0.003); 11.47 ± 11.19 g/dL at day 28 versus
10.86 ± 2.20 g/dL at day 0 in Mali (P = 0.004); and 11.72 ±
1.59 g/dL at day 28 versus 11.32 ± 1.50 g/dL at day 0 in the
Gambia (P = 0.007).
In PP analysis, there were 8/94 (8.5%) treatment failures,
all LPF, in Mali (one at day 21, one at day 28, three at day 35,
and three at day 42); three LTF (3/240) in Senegal (one per
day at days 14, 21, and 35); and 35 LTF in the Gambia (14 at
day 28, eight at day 35, and eight at day 42).
Nevertheless, PCR-corrected ACPR for all sites combined
was 99.3% (3/N), with no recrudescence observed in Mali
and the Gambia and three detected in Senegal, as confirmed
by the 24 SNP molecular barcode analysis (Figure 1). All
patients cleared their infection by day 3. Nevertheless, dur-
ing the study period, parasite clearance was slightly delayed
in Senegal (Figure 2A) and Mali (Figure 2B), but not in the
Gambia (Figure 2C).
HRM assays to determine the prevalence of the mutations
on pfcrt and pfmdr1 genes were performed on 246 genomic
DNA from Senegal and 154 from the Gambia (120 D0 and
34 reinfections). The prevalence of the pfcrt K76T mutation
decreased during the study period in Thies, Senegal (38.5%
in 2011, 26.7% in 2012, 18.5% in 2013) (P = 0.001), whereas
in the Gambia, it tended to increase (30% in 2012 to 50.0% in
2014) (P = 0.08; Table 2). In Senegal, the pfmdr1 mutation
at codon 86 showed a similar trend, with prevalence declined
from 11.5% in 2011 to 2% in 2013 in Thies and 9.4% in
Dakar. No mutation in codons 1042 and 1246 was observed
(Table 2). In the Gambia, as for the pfcrt K76T mutation,
the prevalence of the N86Y mutation increased from 13.6%
in 2012 to 25.9% in 2014 (P = 0.0001); however, the Y184F
mutation decreased 51.7% in 2012 to 25% in 2014 (P = 0.002;
Table 2).
The recurrent infections classified as recrudescence in
three Senegalese patients were wild type in the K13 propel-
ler domain; none of the mutations related to artemisinin
resistance, namely C580Y, R539T, Y493H, I543T, P553T,
V568G, N458Y, was detected. Similarly, in the Gambia, no
mutation in the K13 propeller domain region was observed
in the 154 samples sequenced.
DISCUSSION
AL remains efficacious in west African patients with
uncomplicated P. falciparum malaria, with a cure rate close to
100% given that most recurrent infections were classified as
new ones according to the results of the PCR SNP barcoding.
The identical PCR SNP barcodes observed in the three
(∼1%) suspected treatment failures were from Senegal,
which suggests that these are true treatment failures and
may be attributed to key resistance mutations. For example,
wild-type pfcrt has previously been reported to be associated
with reduced susceptibility to lumefantrine, in line with the
declining trend of the K76T mutation observed in Senegal.
In addition, pfmdr mutations have been reported as associ-
ated with resistance to artemisinin partner drugs.26–32 We did
not find any mutations in the K13 propeller domain region
that correlates with resistance or delayed clearance time to
artemisinin,10,33–35 it may be that these genetic loci are not
responsible in the west African population and therefore fur-
ther population genetic analysis is required to find those
mutations associated with artemisinin resistance in west
Africa. Alternatively, given the late occurrence of the treat-
ment failures during the follow-up period, the possibility
remains that these may be reinfections of parasites harboring
the same genotype in the population.
The treatment failure rates observed in Senegal are also
consistent with previous studies within Senegal.36 However,
other studies from west Africa show slightly higher failure
rates with values of 4% in Senegal,37 5% in Mali,38 > 4% in
Burkina Faso,39 3% in Cote d’Ivoire,40 and 7% in Togo.41
Most of these results are within the confidence intervals and
differences may be attributable to a number of factors,
FIGURE 2. Parasite clearance time. (A) In Senegal, except in
2011, where parasite clearances were obtained by day 1, in 2012,
2013, and 2014, parasite clearances were generally delayed at day 3.
(B) In Mali, during the first years of this study, parasite clearances
were obtained by day 1 in 2012 and 2013, whereas parasite clearance
was delayed by day 2 in 2014. (C) In Gambia, almost all parasite
clearances were obtained by day 1 in 2012, 2013, and 2014.
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including but not limited to regional variations in the dura-
tion of deployment of AL, the period of deployment, the age
distribution of participants, and prevalence levels as well as
drug administration practices.
In the Gambia, the PCR corrected rate showed 100% effi-
cacy; however, the high rate of apparent reinfection observed
is in line with previous reports.42 This can be attributed to a
number of factors, including the intense seasonal transmission
that occurs during the short malaria season in the Gambia. In
addition, poor compliance to treatment at days 2 and 3 may
be a factor, given patients were observed during the three days
of the AL treatment in Mali and Senegal, whereas in the
Gambia, only the first dose was supervised. Most of these late
parasitological failures were identified on days 28, 35, and 42,
with all treated with quinine, the standard second-line drug
for the treatment of P. falciparum malaria in Mali, Senegal,
and the Gambia.
All participants cleared parasitemia in the Gambia by day
1 in 2011, and by day 2 in subsequent years. A similar profile
was observed in Mali. This parasite clearance time obtained in
Mali and the Gambia is considered to be below the threshold
indicating potentially emerging resistance and is comparable
to previous findings from Ethiopia43 and Burkina Faso39 and
is considerably lower than the 21.9% parasitemic patients on
day 3 reported from a trial conducted in western Cambodia as
early as 2007.33 In Senegal, parasite clearance was obtained
by day 3, except in 2011, where parasites were cleared by
day 1. This late parasite clearance time in Senegal compared
with Mali and the Gambia is consistent with the three recru-
descence samples obtained from this country.
At the pfcrt K76T locus, we observed a decrease in the
mutation over the 4 years of the study in Senegal from
38.5% in 2011 to 0% in 2014, consistent with previous find-
ings from Senegal.44–46 Surprisingly, in the Gambia, there
was an increase in the mutation from 30% in 2012 to 37.5%
in 2014, indicating possible continued use of chloroquine out-
side of the government policy. These findings indicate that
there is additional pressure on this locus, and may have
implications for drug use in the Gambia.
CONCLUSION
AL still shows efficacy in west Africa. Antimalarial com-
pounds in use in Senegal and the Gambia (artemisinin deriva-
tives, lumefantrine, and amodiaquine), as well as chloroquine,
are sensitive in vitro to P. falciparum. We observed a general
decrease in pfcrt and pfmdr1 mutations in west Africa among
the populations tested.
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